Genmab Geared Up To Launch Epkinly With AbbVie
As FDA Approves CD20xCD3 Bispecific For Lymphoma
The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.
You may also be interested in...
EMA OKs Seven New Drugs Including First RSV Vaccine For Older Adults
GSK’s Arexvy vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older is among the latest products that the European Medicines Agency said should be approved for use in the EU.
Physicians Ponder CD20 Bispecifics’ Transition To Community As Lunsumio US Debut Approaches
Management of CRS will take getting used to, while B-cell aplasia takes on a new importance in the pandemic era, according to presentations at ASH.
Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.